| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LAX1 |
| Uniprot No | Q8IWV1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-398aa |
| 活性数据 | MDGVTPTLSTIRGRTLESSTLHVTPRSLDRNKDQITNIFSGFAGLLAILLVVAVFCILWNWNKRKKRQVPYLRVTVMPLLTLPQTRQRAKNIYDILPWRQEDLGRHESRSMRIFSTESLLSRNSESPEHVPSQAGNAFQEHTAHIHATEYAVGIYDNAMVPQMCGNLTPSAHCINVRASRDCASISSEDSHDYVNVPTAEEIAETLASTKSPSRNLFVLPSTQKLEFTEERDEGCGDAGDCTSLYSPGAEDSDSLSNGEGSSQISNDYVNMTGLDLSAIQERQLWVAFQCCRDYENVPAADPSGSQQQAEKDVPSSNIGHVEDKTDDPGTHVQCVKRTFLASGDYADFQPFTQSEDSQMKHREEMSNEDSSDYENVLTAKLGGRDSEQGPGTQLLPDE |
| 分子量 | 70.5 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3条关于重组人LAX1蛋白的模拟参考文献(注：因LAX1相关研究较少，以下内容为假设性示例，实际文献请通过学术数据库验证):
1. **文献名称**: "Expression and Functional Analysis of Recombinant Human LAX1 Protein in T-cell Development"
**作者**: Zhang Y, et al. (2022)
**摘要**: 研究通过哺乳动物细胞系统成功表达重组人LAX1蛋白，证实其通过与NOTCH1受体相互作用调控T细胞分化，为免疫细胞发育机制提供新证据。
2. **文献名称**: "LAX1 Promotes Tumor Immune Evasion via PD-L1 Stabilization: Insights from Recombinant Protein Screening"
**作者**: Lee S, et al. (2021)
**摘要**: 利用重组LAX1蛋白进行体外结合实验，发现其通过结合PD-L1抑制泛素化降解，增强肿瘤细胞免疫逃逸能力，为靶向免疫检查点提供新策略。
3. **文献名称**: "Structural Characterization of Recombinant LAX1 Reveals a Novel Leucine-rich Repeat Architecture"
**作者**: Müller J, et al. (2020)
**摘要**: 首次解析重组LAX1蛋白的晶体结构，揭示其非典型LRR结构域特征，并预测其潜在蛋白互作界面，为功能研究提供结构基础。
注：以上为学术场景下的假设文献，实际研究中请通过PubMed/Google Scholar等平台以“LAX1”、“recombinant protein”、“immune regulation”等关键词检索最新成果。
**Background of Recombinant Human LAX1 Protein**
The LAX1 (Lymphocyte Associated Protein X1) gene encodes a transmembrane receptor belonging to the Toll/interleukin-1 receptor (TIR) family, implicated in immune regulation and cell signaling. LAX1 is predominantly expressed in lymphoid tissues and plays a role in lymphocyte development, activation, and survival. Structurally, it contains an extracellular domain with immunoglobulin-like folds, a transmembrane region, and an intracellular TIR domain that mediates downstream signaling, potentially through interactions with adaptor proteins like MyD88. Dysregulation of LAX1 has been associated with hematological malignancies, including acute lymphoblastic leukemia (ALL), where altered expression may contribute to oncogenic signaling pathways.
Recombinant human LAX1 protein is engineered using expression systems (e.g., mammalian, or insect cells) to ensure proper post-translational modifications and functional integrity. It is purified via affinity chromatography, often fused with tags like His or Fc for detection and solubility. This recombinant protein serves as a critical tool for studying LAX1’s role in immune responses, cancer biology, and drug discovery. Applications include ligand-rebinding assays, structural studies, and screening for therapeutic agents targeting LAX1-associated pathways. Its production enables researchers to dissect molecular mechanisms underlying immune disorders and malignancies, offering potential for novel diagnostics and therapies.
×
